Evidence map›Paper›PMID 40999957›Full record

ArticleOncology reports2025

Induction of immunogenic necroptosis by shikonin in drug‑resistant head and neck squamous cell carcinoma cells.

Satsuki Kishita, Naoki Umemura, Hiromi Miyazaki, Makoto Adachi, Hideki Yagi, Emika Ohkoshi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Satsuki KishitaDivision of Immunobiology, Graduate School of Pharmaceutical Sciences, International University of Health and Welfare, Ohtawara, Tochigi 324‑8501, Japan.
Naoki UmemuraDepartment of Oral Biochemistry, Asahi University School of Dentistry, Mizuho, Gifu 501‑0296, Japan.
Hiromi MiyazakiDivision of Biomedical Engineering, National Defense Medical College Research Institute, Saitama, Saitama 359‑8513, Japan.
Makoto AdachiDepartment Oral and Maxillofacial Surgery, Nagoya Tokushukai General Hospital, Kasugai, Aichi 487‑0016, Japan.
Hideki YagiDivision of Immunobiology, Graduate School of Pharmaceutical Sciences, International University of Health and Welfare, Ohtawara, Tochigi 324‑8501, Japan.
Emika OhkoshiDivision of Pharmacognosy, Graduate School of Pharmaceutical Sciences, International University of Health and Welfare, Ohtawara, Tochigi 324‑8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, immune checkpoint inhibitors such as nivolumab have been used to treat recurrent or metastatic head and neck cancer. However, some patients do not respond to nivolumab, and the treatment options for these patients are limited. Therefore, identifying compounds for developing new therapeutic strategies for intractable cancer is important. The acquired multidrug‑resistant metastatic head and neck squamous cell carcinoma cell line, R HSC‑3, expresses refractory cancer‑specific proteins such as the drug excretion transporter, ATP binding cassette subfamily G member 2, the cancer stem cell markers, CD44, SRY‑box transcription factor 9 and Notch, and the poor prognosis factor, fibroblast growth factor 9, and is a useful

Indexed as

Drug Resistance, NeoplasmHead and Neck NeoplasmsNaphthoquinonesNecroptosisSquamous Cell Carcinoma of Head and NeckCell Line, TumorCell SurvivalHumansReactive Oxygen SpeciesNaphthoquinonesReactive Oxygen Speciesshikoninhead and neck squamous cell carcinomaimmunotherapymultidrug resistancenaphthoquinonesnecroptosisoxidative stressreactive oxygen species

Identifiers

PMID40999957
PMCPMC12498129

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.